|Bid||0.1050 x N/A|
|Ask||0.1100 x N/A|
|Day's Range||0.0700 - 0.1150|
|52 Week Range||0.0400 - 0.7300|
|Beta (5Y Monthly)||2.97|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Medivolve, Inc. ("Medivolve" or the "Company") (NEO: MEDV) (OTC: COPRF) (FRA: 4NC), reports, in accordance with the policies of the NEO Exchange, that the nominees listed in the Management Information Circular dated October 22, 2021 for the 2021 Annual and Special Meeting of Shareholders of the Company (the "Meeting") were elected as directors of the Company. 14.12% of all of the issued and outstanding shares of the Company were represented at the Meeting.
Medivolve Inc. ("Medivolve" or the "Company") (NEO: MEDV)(OTC: COPRF)(FRA: 4NC), a healthcare technology company that seeks to reinvent the US healthcare system by leveraging a bespoke telehealth platform, clinical diagnostic network, and data driven AI to improve patient care, today announced financial results for the third quarter ended September 30, 2021.
Medivolve Inc. ("Medivolve" or the "Company") (NEO: MEDV) (FRA: 34C1) is pleased to announce that it has closed the previously announced private placement of an aggregate of 7,142,857 units (the "Units") at a price per Unit of $0.07 (the "Issue Price") for aggregate gross proceeds to the Company of $500,000 (the "Offering").